GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Even though Novo Nordisk warned that copycat versions of its obesity and diabetes drugs would hurt sales in the U.S., second-quarter sales saw a 67% rise year on year. More news covers telehealth ...

U.S.-listed shares of Novo Nordisk (NVO) rose 0.5% in early premarket trading Wednesday after the Danish drugmaker reported ...

The Trump administration is planning to pilot covering weight loss drugs. A longtime healthcare exec moves to a strategic advisory role at General Catalyst.

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...